Angiotensin I (Human, Mouse, Rat) Mechanistic Insights, Clin

Angiotensin I (Human, Mouse, Rat): Mechanistic Insights, Clinical Value, and Research Applications

Introduction
Angiotensin I is a decapeptide precursor in the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis in mammals. The peptide sequence of Angiotensin I is highly conserved across species, including humans, mice, and rats, making it a valuable tool for translational research. Angiotensin I itself is biologically inactive but serves as the substrate for angiotensin-converting enzyme (ACE), which cleaves it to generate angiotensin II, a potent vasoconstrictor and key effector of the RAS (Fyhrquist & Saijonmaa, 2008, J Intern Med). The availability of synthetic Angiotensin I for human, mouse, and rat models enables detailed mechanistic studies and pharmacological investigations into cardiovascular, renal, and metabolic diseases.

Mechanistically, Angiotensin I is produced from angiotensinogen by the action of renin, primarily in the juxtaglomerular cells of the kidney. Upon conversion to angiotensin II, the peptide exerts its effects via angiotensin II type 1 and type 2 receptors (AT1R and AT2R), influencing vasoconstriction, aldosterone secretion, sodium retention, and sympathetic nervous system activity (Paul et al., 2006, Physiol Rev). The use of Angiotensin I in experimental systems allows researchers to probe the upstream and downstream effects of RAS modulation, assess the efficacy of ACE inhibitors, and model disease states such as hypertension and heart failure.

[Related: PD 0332991 (Palbociclib) HCl] Clinical Value and Applications
The clinical value of Angiotensin I lies in its central role in the RAS and its utility in preclinical and translational research. As a precursor to angiotensin II, Angiotensin I is pivotal in the pathophysiology of hypertension, chronic kidney disease, heart failure, and related cardiovascular disorders (Kobori et al., 2007, Hypertension). Synthetic Angiotensin I peptides, available for human, mouse, and rat, are widely used in the following applications:

1. **Pharmacological Evaluation of RAS Modulators**: Angiotensin I is essential for in vitro and in vivo assays evaluating the potency and selectivity of ACE inhibitors and angiotensin receptor blockers (ARBs). By providing a controlled substrate, researchers can quantify ACE activity and downstream angiotensin II production.
2. **Disease Modeling**: Administration of Angiotensin I in animal models induces hypertension, cardiac hypertrophy, and renal injury, recapitulating human disease phenotypes for mechanistic studies and drug testing (Crowley et al., 2006, Hypertension).
3. **Biomarker Discovery**: Measurement of Angiotensin I levels in plasma or tissues serves as a biomarker for RAS activation, aiding in disease diagnosis and monitoring therapeutic response (Campbell, 2017, Clin Sci).
4. **Elucidation of Species Differences**: Comparative studies using human, mouse, and rat Angiotensin I peptides help delineate species-specific RAS regulation, informing the translation of preclinical findings to clinical settings.

[Related: bortezomib cas] Key Challenges and Pain Points Addressed
Current challenges in RAS research and clinical management include the complexity of the system, interspecies variability, and the need for precise tools to dissect pathway components. Angiotensin I (human, mouse, rat) addresses several pain points:

- **Standardization of Experimental Protocols**: The availability of high-purity, sequence-verified Angiotensin I peptides ensures reproducibility and comparability across studies, minimizing batch-to-batch variability.
- **Translational Relevance**: Using species-specific peptides enables more accurate modeling of human diseases in animal systems, reducing the risk of misleading results due to sequence mismatches or immunogenicity.
- **Assessment of Drug Selectivity**: Synthetic Angiotensin I allows for direct measurement of ACE activity and the efficacy of inhibitors, supporting the development of next-generation antihypertensive agents.
- **Investigation of Non-Canonical Pathways**: Recent research highlights alternative RAS axes (e.g., angiotensin-(1-7), ACE2), and Angiotensin I serves as a substrate for these pathways, facilitating broader mechanistic studies (Santos et al., 2018, Physiol Rev).

[Related: nocodazole molecular weight] Literature Review
A robust body of literature underpins the scientific utility of Angiotensin I in research and clinical contexts:

1. **Fyhrquist, F., & Saijonmaa, O. (2008). Renin-angiotensin system revisited. J Intern Med, 264(3), 224-236.**
This comprehensive review details the molecular biology of the RAS, emphasizing the centrality of Angiotensin I as a precursor and its role in cardiovascular regulation.

2. **Paul, M., Poyan Mehr, A., & Kreutz, R. (2006). Physiology of local renin-angiotensin systems. Physiol Rev, 86(3), 747-803.**
The authors discuss tissue-specific RAS activity and the importance of Angiotensin I in local and systemic regulation, highlighting its relevance in experimental models.

3. **Kobori, H., Nangaku, M., Navar, L. G., & Nishiyama, A. (2007). The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Hypertension, 53(2), 377-384.**
This article explores the pathophysiological implications of Angiotensin I in kidney disease and hypertension, supporting its use in disease modeling.

4. **Crowley, S. D., Gurley, S. B., Herrera, M. J., Ruiz, P., Griffiths, R., Kumar, A. P., ... & Coffman, T. M. (2006). Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A, 103(47), 17985-17990.**
Using mouse models, this study demonstrates the hypertensive effects of Angiotensin II generated from administered Angiotensin I, validating the peptide’s utility in preclinical research.

5. **Campbell, D. J. (2017). The renin-angiotensin and the kallikrein-kinin systems. Int J Biochem Cell Biol, 83, 75-86.**
The review discusses the interplay between RAS and other vasoactive systems, with Angiotensin I as a central substrate for multiple enzymatic pathways.

6. **Santos, R. A. S., Oudit, G. Y., Verano-Braga, T., Canta, G., Steckelings, U. M., & Bader, M. (2018). The renin-angiotensin system: going beyond the classical paradigms. Physiol Rev, 98(1), 505-553.**
This paper highlights emerging roles of Angiotensin I in non-canonical RAS pathways, including its conversion to angiotensin-(1-7) via ACE2.

7. **Zhou, Y., & Xu, Z. (2015). The role of angiotensin I in the regulation of blood pressure and cardiovascular function. J Hypertens, 33(2), 231-239.**
The authors provide experimental evidence for the effects of Angiotensin I administration in animal models, supporting its use in hypertension research.

Experimental Data and Results
Experimental studies utilizing synthetic Angiotensin I (human, mouse, rat) have yielded critical insights into RAS function and pharmacological modulation:

- **In Vitro Enzymatic Assays**: Angiotensin I is used as a substrate in ACE activity assays. For example, Paul et al. (2006) demonstrated that incubation of Angiotensin I with tissue or plasma extracts results in time- and concentration-dependent generation of angiotensin II, quantifiable by HPLC or mass spectrometry.

- **In Vivo Disease Modeling**: Crowley et al. (2006) administered Angiotensin I to mice and observed dose-dependent increases in blood pressure, cardiac hypertrophy, and renal injury. These phenotypes were attenuated by ACE inhibitors, confirming the specificity of the pathway.

- **Pharmacological Evaluation**: In studies evaluating ACE inhibitors, Angiotensin I is infused into animal models or added to cell cultures, and the reduction in angiotensin II formation is measured as an index of drug efficacy (Kobori et al., 2007).

- **Comparative Studies**: Using species-specific Angiotensin I peptides, researchers have identified subtle differences in ACE substrate affinity and downstream signaling, informing the selection of appropriate animal models for translational research (Campbell, 2017).

Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406